3888-65-1

Basic information

• Product Name: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE
• Synonyms: 4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE;4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE HYDROCHLORIDE;4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL;4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE;4-(FLUOROPHENYL)-4-HYDROXYLPIPERIDINE HYDROCHLORIDE;4-(FLUOROPHENYL)-4-HYDROXYPIPERIDINE;4-(FLUOROPHENYL)-4-HYDROXYPIPERIDINE HYDROCHLORIDE;4-(p-Fluorophenyl)-4-piperidinol
• CAS NO: 3888-65-1
• Molecular Formula: C₁₁H₁₄FNO
• Molecular Weight: 195.24
• EINECS: 223-431-8
• Mol File: 3888-65-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 116.4-117.6℃
• Boiling Point: 313.4 °C at 760 mmHg
• Flash Point: 143.3 °C
• Appearance: /Solid
• Density: 1.173 g/cm³
• Vapor Pressure: 0.000212mmHg at 25°C
• CAS DataBase Reference: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE(3888-65-1)
• EPA Substance Registry System: 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE(3888-65-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 3888-65-1(Hazardous Substances Data)

Usage

Description

4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE is a chemical compound that serves as a reagent and intermediate in the synthesis of various pharmaceutical products. It is characterized by the presence of a 4-fluorophenyl group attached to a piperidin-4-ol structure, which contributes to its unique properties and potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE is used as a reagent for the discovery of AZD3514, an androgen receptor downregulator, for the treatment of advanced prostate cancer. Its role in the development of this drug highlights its importance in the field of oncology and the potential for further research and development of novel cancer therapies.
Additionally, 4-(4-FLUORO-PHENYL)-PIPERIDIN-4-OL HYDROCHLORIDE functions as an intermediate in the synthesis of haloperidol (H103700), a medication with antidyskinetic, antipsychotic, and neuroprotective properties. This demonstrates its versatility in the development of drugs targeting various medical conditions, including movement disorders and mental health disorders.

InChI:InChI=1/C11H14FNO.ClH/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11;/h1-4,13-14H,5-8H2;1H

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 163631-02-5 1-benzyl-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 553631-05-3 tert-butyl 4-hydroxy-4-(4-fluorophenyl)-1-piperidinecarboxylate 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 352-13-6 4-flourophenylmagnesium bromide 
• 82387-58-4 1-(Ethoxycarbonyl)-4-(4-fluorophenyl)piperidin-4-ol 
• 710-90-7 4-Brom-4-(4-fluor-phenyl)-piperidin 

Downstream Products

• 803-45-2 4-<4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl>-1-(4-fluorophenyl)-1-butanone 
• 95948-65-5 SGT₅₄₂ 
• 1026235-61-9 2-[4-(4-Fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 
• 156782-58-0 6-[2S*-(4-Hydroxy-4-(4-fluorophenyl)piperidino)-1S*-hydroxypropyl]-3, 4-dihydro-2(1H)-quinolone mesylate 
• 1207865-20-0 C₂₉H₂₃Cl₂FN₄O₂ 
• 1584-50-5 1-(4-chlorophenyl)-4-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one 
• 2560-41-0 SGT₅₄₁ 
• 77872-51-6 3-{2-[4-(4-Fluoro-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-1H-indol-4-ol 
• 178375-24-1 1-(3-methyl-4-triisopropylsilyloxyphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-propan-1-one 

Relevant articles and documents

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.